Patents by Inventor Brenda L. Stevens
Brenda L. Stevens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952427Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: March 15, 2022Date of Patent: April 9, 2024Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
-
Publication number: 20240041995Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: ApplicationFiled: November 2, 2022Publication date: February 8, 2024Inventors: John J. ENGELHARDT, Mark J. SELBY, Alan J. KORMAN, Mary Diane FEINGERSH, Brenda L. STEVENS
-
Patent number: 11529399Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: GrantFiled: October 14, 2019Date of Patent: December 20, 2022Assignee: Bristol-Myers Squibb CompanyInventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
-
Publication number: 20220324989Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: March 15, 2022Publication date: October 13, 2022Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS, James William WEST
-
Publication number: 20220185877Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: January 7, 2022Publication date: June 16, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
-
Patent number: 11306149Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: December 27, 2018Date of Patent: April 19, 2022Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
-
Patent number: 11254740Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: GrantFiled: June 10, 2019Date of Patent: February 22, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
-
Patent number: 11207391Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: GrantFiled: March 13, 2019Date of Patent: December 28, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
-
Publication number: 20210054091Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: November 6, 2020Publication date: February 25, 2021Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS
-
Patent number: 10898556Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: GrantFiled: April 5, 2018Date of Patent: January 26, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
-
Patent number: 10844130Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: April 30, 2019Date of Patent: November 24, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
-
Publication number: 20200339700Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: December 27, 2018Publication date: October 29, 2020Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS, James William WEST
-
Publication number: 20200071412Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: November 18, 2019Publication date: March 5, 2020Applicants: The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANYInventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
-
Publication number: 20200040072Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: June 10, 2019Publication date: February 6, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
-
Publication number: 20200030425Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: ApplicationFiled: October 14, 2019Publication date: January 30, 2020Inventors: John J. ENGELHARDT, Mark J. SELBY, Alan J. KORMAN, Mary Diane FEINGERSH, Brenda L. STEVENS
-
Patent number: 10493140Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: GrantFiled: February 21, 2019Date of Patent: December 3, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
-
Patent number: 10479838Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: June 28, 2016Date of Patent: November 19, 2019Assignees: Bristol-Myers Squibb Company, The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
-
Publication number: 20190298816Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: ApplicationFiled: March 13, 2019Publication date: October 3, 2019Inventors: John J. ENGELHARDT, Mark J. SELBY, Alan J. KORMAN, Mary Diane FEINGERSH, Brenda L. STEVENS
-
Publication number: 20190248911Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
-
Patent number: 10358489Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: GrantFiled: June 12, 2017Date of Patent: July 23, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell